DR. HOWARD LEE WEINER, MD
Medical Practice at Brookline Pl, Brookline, MA
License number
Massachusetts 33311
Category
Medical Practice
Type
Neurological Surgery
Address
Address
2
1 Brookline Pl SUITE 227, Brookline, MA 02445
77 Brigham And WOMEN'S HOSPITAL, Boston, MA 02115
77 Brigham And WOMEN'S HOSPITAL, Boston, MA 02115
Phone
(617) 525-6550
(617) 525-5300
(617) 525-5252 (Fax)
(617) 525-5300
(617) 525-5252 (Fax)
Personal information
See more information about HOWARD LEE WEINER at radaris.comName
Address
Phone
72 Colbourne Cres, Brookline, MA 02445
5 Winslow St, Provincetown, MA 02657
114 Somerset Rd, Brookline, MA 02445
106 Village Post Rd, Danvers, MA 01923
51 Raymond Rd, Salem, MA 01970
Professional information
Suppression Of T-Cell Proliferation Using Peptide Fragments Of Myelin Basic Protein
US Patent:
6036957, Mar 14, 2000
Filed:
Jun 6, 1995
Appl. No.:
8/469640
Inventors:
Howard L. Weiner - Brookline MA
David A. Hafler - West Newton MA
Ariel Miller - Ahuza, IL
Ahmad Al-Sabbagh - Norwood MA
David A. Hafler - West Newton MA
Ariel Miller - Ahuza, IL
Ahmad Al-Sabbagh - Norwood MA
Assignee:
Autoimmune, Inc. - Lexington MA
International Classification:
A61K 3900, A61K 3817, C07K 708, C07K 1447
US Classification:
4241841
Abstract:
Peptides are administered to individuals suffering from multiple sclerosis. The peptides contain immunodominant epitopes of myelin basic protein that are recognized by T-cells from relapsing-remitting multiple sclerosis patients, and that are contained in the 84-102 and 143-168 regions of human MBP.
Method Of Treating Or Preventing Type 1 Diabetes By Oral Administration Of Insulin
US Patent:
5843886, Dec 1, 1998
Filed:
Jun 2, 1995
Appl. No.:
8/461588
Inventors:
Howard L. Weiner - Brookline MA
George Eisenbarth - Wellesley MA
David Allen Hafler - West Newton MA
Zhengi Zhang - Walden MA
George Eisenbarth - Wellesley MA
David Allen Hafler - West Newton MA
Zhengi Zhang - Walden MA
Assignee:
Autoimmune, Inc. - Lexington MA
International Classification:
A61K 3828
US Classification:
514 3
Abstract:
Disclosed herein are methods for treating or preventing a disease in mammals having the characteristics of Type 1 diabetes comprising administering insulin or disease suppressive fragments of insulin or analogs thereof in oral or aerosol dosage forms to said mammals. Also disclosed herein are pharmaceutical formulation or dosage forms for use in the methods.
Treatment Of Autoimmune Diseases By Aerosol Administration Of Autoantigens
US Patent:
5571499, Nov 5, 1996
Filed:
Jun 6, 1995
Appl. No.:
8/465815
Inventors:
David A. Hafler - W. Newton MA
Howard L. Weiner - Brookline MA
Howard L. Weiner - Brookline MA
Assignee:
Autoimmune, Inc. - Lexington MA
International Classification:
A61K 912, A61K 3802
US Classification:
414 43
Abstract:
Disclosed herein is a method for treating autoimmune diseases in mammals by administration of one or more agents selected from the group consisting of autoantigens specific for the autoimmune disease, disease-suppressive fragments and analogs of said autoantigen in aerosol form.
Bystander Suppression Of Autoimmune Diseases
US Patent:
2004011, Jun 17, 2004
Filed:
Aug 11, 2003
Appl. No.:
10/639286
Inventors:
Howard Weiner - Brookline MA, US
Ariel Miller - Haifa, IL
Zhengyi Zhang - Needham MA, US
Ahmad Al-Sabbagh - Norwood MA, US
Ariel Miller - Haifa, IL
Zhengyi Zhang - Needham MA, US
Ahmad Al-Sabbagh - Norwood MA, US
Assignee:
Autolmmune Inc.
International Classification:
C12Q001/68, A61K039/00
US Classification:
424/185100
Abstract:
This invention pertains to an improvement in the treatment of autoimmune diseases. More specifically, the invention is directed to the use of bystander antigens (i.e. antigens that suppress cells involved in the autoimmune process) for the treatment of autoimmune diseases. The invention also includes pharmaceutical formulations comprising bystander antigens useful in the treatment of autoimmune diseases in mammals.
Method Of Treating Or Preventing Type 1 Diabetes By Oral Administration Of Insulin
US Patent:
5643868, Jul 1, 1997
Filed:
Jun 6, 1995
Appl. No.:
8/472016
Inventors:
Howard L. Weiner - Brookline MA
George Eisenbarth - Wellesley MA
David Allen Hafler - West Newton MA
Zhengyi Zhang - Walden MA
George Eisenbarth - Wellesley MA
David Allen Hafler - West Newton MA
Zhengyi Zhang - Walden MA
Assignee:
Autoimmune, Inc. - Lexington MA
International Classification:
A61K 3820, A61K 3900, C07K 1462
US Classification:
514 3
Abstract:
Disclosed herein are methods for treating or preventing a disease in mammals having the characteristics of Type 1 diabetes comprising administering insulin or disease suppressive fragments of insulin or analogs thereof in oral or aerosol dosage forms to said mammals. Also disclosed herein are pharmaceutical formulation or dosage forms for use in the methods.
Treatment Of Multiple Sclerosis By Oral Administration Of Autoantigens
US Patent:
5869054, Feb 9, 1999
Filed:
May 31, 1995
Appl. No.:
8/454832
Inventors:
Howard L. Weiner - Brookline MA
David A. Hafler - Newton MA
David A. Hafler - Newton MA
Assignee:
Autoimmune Inc. - Lexington MA
International Classification:
A61K 3900
US Classification:
4241841
Abstract:
The invention is directed to a method of treating a T cell-mediated autoimmune disease in animals, including humans, by the oral or enteral administration of autoantigens, fragments of autoantigens, or analogs structurally related to those autoantigens, which are specific for the particular autoimmune disease. The method of the invention includes both prophylactic and therapeutic measures.
Treatment Of Autoimmune Arthritis By Oral Administration Of Collagen
US Patent:
6019971, Feb 1, 2000
Filed:
Jun 5, 1995
Appl. No.:
8/463946
Inventors:
Howard L. Weiner - Brookline MA
David A. Hafler - W. Newton MA
David A. Hafler - W. Newton MA
Assignee:
AutoImmune Inc. - Lexington MA
International Classification:
A61K 3900, A61K 3702, A61K 3712
US Classification:
4241841
Abstract:
The invention is directed to a method of treating a T cell-mediated autoimmune disease in animals, including humans, by the oral administration of autoantigens, fragments of autoantigens, or analogs structurally related to those autoantigens, which are specific for the particular autoimmune disease. The method of the invention includes both prophylactic and therapeutic measures.
Treatment Of Multiple Sclerosis Using Cop-1 And Th2-Enhancing Cytokines
US Patent:
2001000, Jul 12, 2001
Filed:
Feb 6, 2001
Appl. No.:
09/777582
Inventors:
Howard Weiner - Brookline MA, US
Ruth Marron - Brookline MA, US
Anthony Slavin - Boston MA, US
Ruth Marron - Brookline MA, US
Anthony Slavin - Boston MA, US
Assignee:
Autoimmune, Inc.
International Classification:
A61K038/00, C12P021/06, A61K045/00
US Classification:
435/069100, 424/085200, 514/012000
Abstract:
The invention relates to a treatment for multiple sclerosis. COP-1 (copolymer-1), a synthetic polymer consisting of a mixture of random synthetic polypeptides composed of L-alanine, L-glutamic acid, L-lysine and L-tyrosine in a molar ratio of about 6:2:5:1, is administered mucosally to patients afflicted with the disease in combination with Th2 enhancing cytokines such as IL-4 or IL-10. The combination treatment of IL-4 or IL-10 (preferably orally administered) with mucosally administered COP-1 shows a substantially greater suppressive effect than does treatment with cytokine or COP-1 alone.
Method Of Treating Or Preventing Type 1 Diabetes By Oral Administration Of Insulin
US Patent:
5858968, Jan 12, 1999
Filed:
Jun 2, 1995
Appl. No.:
8/461585
Inventors:
Howard L. Weiner - Brookline MA
George Eisenberth - Wellesley MA
David Allen Hafler - West Newton MA
Zhengi Zhang - Walden MA
George Eisenberth - Wellesley MA
David Allen Hafler - West Newton MA
Zhengi Zhang - Walden MA
Assignee:
AutoImmune Inc. - Lexington MA
International Classification:
A61K 3828
US Classification:
514 3
Abstract:
Disclosed herein are methods for treating or preventing a disease in mammals having the characteristics of Type 1 diabetes comprising administering insulin or disease suppressive fragments of insulin or analogs thereof in oral or aerosol dosage forms to said mammals. Also disclosed herein are pharmaceutical formulation or dosage forms for use in the methods.
Modulation Of The Immune Response
US Patent:
2011026, Oct 27, 2011
Filed:
Mar 19, 2009
Appl. No.:
12/933800
Inventors:
Howard Weiner - Brookline MA, US
Francisco J. Quintana - Jamaica Plain MA, US
Francisco J. Quintana - Jamaica Plain MA, US
International Classification:
A61K 31/407, A61K 35/26, A61K 39/395, A61K 39/00, A61K 39/12, A61K 39/02, A61K 39/002, A61P 37/02, A61P 35/00, A61P 31/12, A61P 31/04, A61P 31/10, A61P 33/02, A61K 31/352, C12N 5/00
US Classification:
4241721, 435375, 424 937, 514410, 4241781, 4241841, 4242041, 4242341, 4242741, 4242691, 514455
Abstract:
Methods for increasing the generation of IL-17-producing T cells (T17) in vivo and in vitro, and enriched populations of T17 cells for the treatment of diseases benefiting from an induced or enhanced immune response, e.g., infection and cancer.